Advising biotech and pharma clients across R&D, clinical trials, regulatory interactions (FDA and international), and development strategy across multiple therapeutic areas.

Led biotech start-up developing genetically engineered bacteria for novel protein therapeutics. Directed business strategy, scientific development, and investor relations.

Provided medical and regulatory strategy for multiple global health programs. Supported drug development, medical affairs, and global distribution of therapies in underserved regions.

Led development programs for flubendazole (onchocerciasis) and pediatric mebendazole (soil-transmitted helminthiasis). Secured regulatory approval and WHO adoption of new pediatric formulation.

Managed a global portfolio of 80+ marketed products. Directed line extensions, pediatric exclusivity programs, reformulations, and regulatory initiatives.

Led R&D and pharmacovigilance for multiple therapeutic areas, including Tylenol line extensions, ADHD (Concerta approval), sickle cell anemia, and cystic fibrosis.